A Phase 4 interventional study of a prebiotic, that us a standardized extract of cultured Lentinula edodes mycelia and Placebo in Respiratory Tract Infections (RTI), sponsored by Hasanuddin University. Not yet recruiting. Open to participants aged 4 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Hasanuddin University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a study to evaluate the effects of a prebiotic, AHCC, a standardized extract of cultured Lentinula edodes mycelia, on immunologic markers and the incidence of respiratory tract infections in children.
A three-month, randomized, double-blind, placebo-controlled, pilot study will be performed in Indonesian healthy children aged 4 to 6 years in Nursery Schools. Subjects will be administered dextrin alone (placebo) or dextrin including AHCC. The incidence of RTI will be the primary outcome, and changes in serum Interferon Gamma (IFN-γ) as the crucial cytokine that acts as anti infective in the immune system will be the secondary outcome. Following completion of the 3 months intervention, participants will enter a 5 months follow up period (Months 4-8). New onset adverse events, ongoing adverse events, serious adverse events, and investigator assessed intervention related adverse events will be collected and evaluated.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
This study's planned enrollment of 60 is below the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Browse Respiratory Tract Infections studies →Hasanuddin University is the lead sponsor of 71 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is the control arm of the intervention study. Subjects will be administered placebo
Dietary Supplement: Placebo
This is the active arm of the intervention study.Subjects will be administered AHCC.
Dietary Supplement: a prebiotic, that us a standardized extract of cultured Lentinula edodes mycelia
Subjects will be administered AHCC.
Also known as: AHCC
Subjects will be administered placebo
Incidence of Respiratory Tract Infection
the number incidence of infections, specifically respiratory tract infection, by looking at the number of febrile days (\>37.5 ◦C) during the test period.
Time frame: 3 months
additional immunological effects
immunomodulatory effects of AHCC, we will be checking serum IFN-γ as a biomarker of immunity at baseline and 3 months after AHCC using enzyme-linked immunosorbent assay (ELISA).
Time frame: 3 months
additional nutritional effect- WAZ score
changes in weight-for-age z-score as sign of growth and nutritional status.
Time frame: 3 months
additional nutritional effect- Weight in gram
changes in weight in gram as sign of growth and nutritional status.
Time frame: 3 months
additional nutritional effect- HAZ score
changes in height-for-age z-score as sign of growth and nutritional status.
Time frame: 3 months
additional nutritional effect- Height in cm
changes in height in cm as sign of growth and nutritional status.
Time frame: 3 months
additional nutritional effect- WHZ score
changes in weight-for-height z-score as sign of growth and nutritional status.
Time frame: 3 months
additional nutritional effect- Head circumference in cm
changes in head circumference in cm as sign of growth and nutritional status.
Time frame: 3 months
compliance and adherence rates
evaluate compliance and adherence rates to the intervention and their association with study outcomes. The secondary outcome measures include: * The count of days missed from Daycare Centers due to symptoms of the common cold symptoms * The duration of fever and cough during viral infections * Any side effects linked to the consumption of AHCC.
Time frame: 3 months
Caregiver-reported adherence
Adherence monitored through daily intake logs, home visits, and telephone follow-ups
Time frame: 3 months
Incidence of adverse events
Adverse events data collection during and post intervention
Time frame: Baseline through Month 8 (including 5 months post intervention follow up)
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 29 phase 4 interventional studies under Respiratory Tract Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 51. This study's planned 3 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Active Hexose Correlated Compound
Respiratory Tract Infections →
Hasanuddin University